Lead Product(s): Faricimab
Therapeutic Area: Ophthalmology Product Name: RG7716
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Faricimab is the first investigational bispecific antibody designed for the eye) It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) – that drive a number of retinal conditions.
Lead Product(s): Clobetasol Propionate
Therapeutic Area: Ophthalmology Product Name: APP13007
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Formosa Laboratories, Inc.
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Agreement March 11, 2021
First patient is dosed in a 370-patient in Phase 3 trial of APP13007 in the US. Sosei Heptares will receive undisclosed milestone payments based on progression of Activus' pipeline and royalties from the commercialization of certain products should they reach the market.